We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

0 hedge funds and large institutions have $0 invested in Ambrx Biopharma Inc in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 68 → 0 (-68)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital invested

Capital invested by funds: $913M → $0 (-$913M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 68

Holders
–
Holders Change
-68
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
68
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
-$238M
2
CAM
Cormorant Asset Management
Massachusetts
-$160M
3
PBA
Paradigm Biocapital Advisors
New York
-$62M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$60.4M
5
DTC
Deep Track Capital
Connecticut
-$52.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
– -$3.68M -258,364 Closed
MIM
27
Monashee Investment Management
Massachusetts
– -$2.95M -207,500 Closed
HS
28
HighVista Strategies
Massachusetts
– -$2.89M -203,122 Closed
Barclays
29
Barclays
United Kingdom
– -$2.85M -199,950 Closed
ECM
30
ExodusPoint Capital Management
New York
– -$2.01M -140,842 Closed
TD Asset Management
31
TD Asset Management
Ontario, Canada
– -$2M -140,256 Closed
SC
32
Stempoint Capital
New York
– -$1.8M -126,101 Closed
LIP
33
Lighthouse Investment Partners
Florida
– -$1.27M -88,925 Closed
PHP
34
Parkman Healthcare Partners
Connecticut
– -$1.25M -87,678 Closed
Geode Capital Management
35
Geode Capital Management
Massachusetts
– -$1.16M -81,157 Closed
PA
36
Perceptive Advisors
New York
– -$1.12M -78,811 Closed
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$1.1M -77,472 Closed
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
– -$998K -70,094 Closed
CCM
39
Connective Capital Management
California
– -$829K -58,189 Closed
HP
40
HealthInvest Partners
Sweden
– -$824K -57,847 Closed
Renaissance Technologies
41
Renaissance Technologies
New York
– -$768K -53,900 Closed
NM
42
NWI Management
New York
– -$764K -53,645 Closed
SVCM
43
Saturn V Capital Management
Texas
– -$752K -52,781 Closed
Morgan Stanley
44
Morgan Stanley
New York
– -$720K -50,552 Closed
State Street
45
State Street
Massachusetts
– -$712K -50,015 Closed
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
– -$701K -49,203 Closed
ACP
47
Altitude Crest Partners
Connecticut
– -$614K -43,100 Closed
SSA
48
Sierra Summit Advisors
Nevada
– -$530K -37,237 Closed
Bank of America
49
Bank of America
North Carolina
– -$523K -36,733 Closed
FAM
50
Fred Alger Management
New York
– -$468K -32,886 Closed
1
2
3

AMAM Hedge Fund Activity: Q1 2024 in Review

0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2024, worth a combined $0 — down 100% from $913M a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of AMAM and 0 opened new positions — a net loss of 68 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Darwin Global Management, exiting entirely with an estimated $238M sold.

  • 0 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2024, down from 68 in Q4 2023.
  • Funds reported $0 of Ambrx Biopharma Inc stock for Q1 2024, down 100% quarter-over-quarter.
  • 0 funds opened new Ambrx Biopharma Inc positions in Q1 2024 and 68 closed out, a net change of -68 holders.
  • The largest Ambrx Biopharma Inc seller in Q1 2024 was Darwin Global Management, an estimated $238M sold.

Based on aggregated 13F filings for Q1 2024.